Compare Stocks: HLVX, PRLD, RCKT, and XFOR

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
HLVX HilleVax	$2.09	$2.09	$1.77 ▼ $2.17	$104.79M	0.77	532,880 shs	N/A
PRLD Prelude Therapeutics	$5.37 -1.7%	$5.07	$0.98 ▼ $6.83	$428.13M	0.97	426,117 shs	122,621 shs
RCKT Rocket Pharmaceuticals	$3.75 -3.0%	$3.58	$2.53 ▼ $5.45	$411.11M	0.5	2.58 million shs	490,212 shs
XFOR X4 Pharmaceuticals	$3.22 -20.4%	$4.08	$2.80 ▼ $4.83	$400.55M	0.39	563,315 shs	1.52 million shs

7 Stocks to Buy Before the Robotics Revolution

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
HLVX HilleVax	0.00%	0.00%	0.00%	0.00%	-0.48%
PRLD Prelude Therapeutics	0.00%	-2.50%	+11.43%	+38.58%	+343.90%
RCKT Rocket Pharmaceuticals	0.00%	+3.76%	+6.93%	+45.66%	+17.68%
XFOR X4 Pharmaceuticals	0.00%	0.00%	-12.93%	+4.94%	+15.43%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
HLVX HilleVax	$2.09	$2.09	$1.77 ▼ $2.17	$104.79M	0.77	532,880 shs	N/A
PRLD Prelude Therapeutics	$5.37 -1.7%	$5.07	$0.98 ▼ $6.83	$428.13M	0.97	426,117 shs	122,621 shs
RCKT Rocket Pharmaceuticals	$3.75 -3.0%	$3.58	$2.53 ▼ $5.45	$411.11M	0.5	2.58 million shs	490,212 shs
XFOR X4 Pharmaceuticals	$3.22 -20.4%	$4.08	$2.80 ▼ $4.83	$400.55M	0.39	563,315 shs	1.52 million shs

7 Stocks to Buy Before the Robotics Revolution

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
HLVX HilleVax	0.00%	0.00%	0.00%	0.00%	-0.48%
PRLD Prelude Therapeutics	0.00%	-2.50%	+11.43%	+38.58%	+343.90%
RCKT Rocket Pharmaceuticals	0.00%	+3.76%	+6.93%	+45.66%	+17.68%
XFOR X4 Pharmaceuticals	0.00%	0.00%	-12.93%	+4.94%	+15.43%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
HLVX HilleVax	0.00	N/A	N/A	N/A
PRLD Prelude Therapeutics	2.40	Hold	$7.67	41.92% Upside
RCKT Rocket Pharmaceuticals	2.30	Hold	$8.57	129.49% Upside
XFOR X4 Pharmaceuticals	2.50	Moderate Buy	$11.25	225.62% Upside

Current Analyst Ratings Breakdown

Latest HLVX, PRLD, RCKT, and XFOR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/1/2026	RCKT Rocket Pharmaceuticals	Chardan Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$11.00
8/25/2026	XFOR X4 Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/11/2026	RCKT Rocket Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/11/2026	XFOR X4 Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/11/2026	RCKT Rocket Pharmaceuticals	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Outperform	$16.00 ➝ $15.00
7/29/2026	PRLD Prelude Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/29/2026	PRLD Prelude Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$8.00
7/28/2026	XFOR X4 Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/15/2026	RCKT Rocket Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/15/2026	PRLD Prelude Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
7/10/2026	XFOR X4 Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)

(Data available from 9/8/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
HLVX HilleVax	N/A	N/A	N/A	N/A	$3.10 per share	N/A
PRLD Prelude Therapeutics	$12.14M	35.51	N/A	N/A	$1.09 per share	4.96
RCKT Rocket Pharmaceuticals	N/A	N/A	N/A	N/A	$2.56 per share	N/A
XFOR X4 Pharmaceuticals	$35.11M	9.76	N/A	N/A	$2.13 per share	1.62

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
HLVX HilleVax	-$147.27M	-$1.43	N/A	N/A	N/A	N/A	-34.29%	-28.50%	N/A
PRLD Prelude Therapeutics	-$99.50M	-$0.73	N/A	N/A	N/A	N/A	-75.35%	-44.39%	11/11/2026 (Estimated)
RCKT Rocket Pharmaceuticals	-$223.12M	-$0.17	N/A	N/A	N/A	N/A	-52.77%	-44.92%	11/5/2026 (Estimated)
XFOR X4 Pharmaceuticals	-$79.20M	-$1.20	N/A	N/A	N/A	-568.80%	-63.05%	-36.89%	11/4/2026 (Estimated)

Latest HLVX, PRLD, RCKT, and XFOR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2026	Q2 2026	PRLD Prelude Therapeutics	-$0.1967	-$0.14	+$0.0567	-$0.14	$5.70 million	$5.70 million
8/10/2026	Q2 2026	RCKT Rocket Pharmaceuticals	$0.86	$1.08	+$0.22	$1.08	$0.22 million	N/A
8/6/2026	Q2 2026	XFOR X4 Pharmaceuticals	-$0.1760	-$0.13	+$0.0460	-$0.13	$2.42 million	$8.81 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
HLVX HilleVax	N/A	N/A	N/A	N/A	N/A
PRLD Prelude Therapeutics	N/A	N/A	N/A	N/A	N/A
RCKT Rocket Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
XFOR X4 Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
HLVX HilleVax	N/A	26.39	26.39
PRLD Prelude Therapeutics	N/A	4.07	4.07
RCKT Rocket Pharmaceuticals	0.05	9.24	9.24
XFOR X4 Pharmaceuticals	0.49	11.30	11.02

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
HLVX HilleVax	86.42%
PRLD Prelude Therapeutics	79.72%
RCKT Rocket Pharmaceuticals	98.39%
XFOR X4 Pharmaceuticals	72.03%

Insider Ownership

Company	Insider Ownership
HLVX HilleVax	24.90%
PRLD Prelude Therapeutics	49.20%
RCKT Rocket Pharmaceuticals	21.30%
XFOR X4 Pharmaceuticals	1.13%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
HLVX HilleVax	20	50.14 million	37.66 million	Not Optionable
PRLD Prelude Therapeutics	120	79.80 million	40.54 million	Optionable
RCKT Rocket Pharmaceuticals	240	109.78 million	86.39 million	Optionable
XFOR X4 Pharmaceuticals	80	99.15 million	98.03 million	No Data

HLVX, PRLD, RCKT, and XFOR Headlines

Recent News About These Companies

X4 Pharmaceuticals Announces Positive Outcome From FDA Type C Meeting And Provides Update On 4WARD Phase 3 Chronic Neutropenia Trial

3 hours ago | marketscreener.comM

X4 Pharmaceuticals Announces Positive Outcome from FDA Type C Meeting

September 8 at 7:00 AM | globenewswire.com

Braidwell LP Sells 350,200 Shares of X4 Pharmaceuticals, Inc. $XFOR

September 3, 2026 | marketbeat.com

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

September 1, 2026 | globenewswire.com

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Receives Average Rating of "Moderate Buy" from Analysts

August 19, 2026 | marketbeat.com

X4 Pharmaceuticals (NASDAQ:XFOR) President Sells $109,117.44 in Stock

August 14, 2026 | insidertrades.com

John Volpone Sells 24,576 Shares of X4 Pharmaceuticals (NASDAQ:XFOR) Stock

August 13, 2026 | marketbeat.com

X4 Pharmaceuticals (NASDAQ:XFOR) Chairman Sells $210,615.84 in Stock

August 13, 2026 | marketbeat.com

X4 Pharmaceuticals (XFOR) Upgraded to Buy: Here's Why

August 11, 2026 | zacks.com

XFOR Q3 EPS Estimate Lifted by Brookline Capital Markets

August 11, 2026 | marketbeat.com

Equities Analysts Issue Forecasts for XFOR FY2029 Earnings

August 10, 2026 | marketbeat.com

X4 Pharmaceuticals (XFOR) Receives a Buy from Stifel Nicolaus

August 9, 2026 | theglobeandmail.com

X4 Pharmaceuticals: Q2 Earnings Snapshot

August 6, 2026 | chron.com

X4 Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Corporate Update

August 6, 2026 | markets.businessinsider.com

X4 Pharmaceuticals (XFOR) Reports Q2 Loss, Beats Revenue Estimates

August 6, 2026 | zacks.com

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

August 3, 2026 | globenewswire.com

X4 Pharmaceuticals, Inc. Common Stock (XFOR) After Hours Quote

July 13, 2026 | nasdaq.com

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

July 7, 2026 | globenewswire.com

X4 Pharmaceuticals (NASDAQ:XFOR) CFO David Kirske Sells 8,543 Shares

July 2, 2026 | insidertrades.com

X4 Pharmaceuticals Appoints Kelly Gold, Experienced Chief Financial Officer, to its Board of Directors

July 1, 2026 | globenewswire.com

Why X4 Pharmaceuticals, Inc.’s (XFOR) Stock Is Up 5.01%

June 26, 2026 | aaii.comA

New MarketBeat Followers Over Time

Media Sentiment Over Time

HLVX, PRLD, RCKT, and XFOR Company Descriptions

HilleVax NASDAQ:HLVX

HilleVax, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. It develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company was formerly known as MokshaCo, Inc. and changed its name to HilleVax, Inc. in February 2021. HilleVax, Inc. was founded in 2019 and is headquartered in Boston, Massachusetts.

Prelude Therapeutics NASDAQ:PRLD

$5.36 -0.10 (-1.74%)

As of 03:06 PM Eastern

Prelude Therapeutics Incorporated, a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT1419, a myeloid cell leukemia-1 inhibitor, which is in Phase 1 clinical trial for the treatment of selected relapsed/refractory myeloid or B-cell malignancies; PRT2527, a cyclin-dependent kinase, which is in Phase 1 clinical trial for the treatment of advanced solid tumors; PRT3645, a cyclin-dependent kinase 4/6 inhibitor, which is in Phase 1 clinical trial for the treatment of advanced and metastatic solid tumors; and PRT3879, a SMARCA2 selective protein degrader, which is in Phase 2/3 clinical trial for the treatment of advanced and metastatic solid tumors with loss of SMARCA4 due to truncating mutation and/or deletion. The company's CDK9 program is a regulator of cancer-promoting transcriptional programs, including MCL1, MYC and MYB. Prelude Therapeutics Incorporated was incorporated in 2016 and is based in Wilmington, Delaware.

Rocket Pharmaceuticals NASDAQ:RCKT

$3.74 -0.12 (-2.98%)

As of 03:07 PM Eastern

Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia. The company also has a clinical stage in vivo adeno-associated virus program for Danon disease, a multi-organ lysosomal-associated disorder leading to early death due to heart failure; Plakophilin-2 Arrhythmogenic Cardiomyopathy, an inheritable cardiac disorder; and BAG3 Dilated Cardiomyopathy. It has license agreements with Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, Centro de Investigacion Biomedica En Red, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; UCL Business PLC; The Regents of the University of California; and REGENXBIO, Inc. Rocket Pharmaceuticals, Inc. was founded in 1999 and is headquartered in Cranbury, New Jersey.

X4 Pharmaceuticals NASDAQ:XFOR

$3.22 -0.83 (-20.42%)

As of 03:06 PM Eastern

X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia. The company is also developing X4P-003, a CXCR4 antagonist for the treatment of CXCR4 dependent disorders and primary immunodeficiencies; and X4P-002, a CXCR4 antagonist for the treatment of blood-brain barrier diseases. It has a license agreement with Abbisko Therapeutics Co Ltd. to develop, manufacture, and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications. The company is headquartered in Boston, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest HLVX, PRLD, RCKT, and XFOR Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest HLVX, PRLD, RCKT, and XFOR Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

HLVX, PRLD, RCKT, and XFOR Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

HLVX, PRLD, RCKT, and XFOR Company Descriptions

HilleVax NASDAQ:HLVX

Prelude Therapeutics NASDAQ:PRLD

Rocket Pharmaceuticals NASDAQ:RCKT

X4 Pharmaceuticals NASDAQ:XFOR

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest HLVX, PRLD, RCKT, and XFOR Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest HLVX, PRLD, RCKT, and XFOR Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

HLVX, PRLD, RCKT, and XFOR Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

HLVX, PRLD, RCKT, and XFOR Company Descriptions

HilleVax NASDAQ:HLVX

Prelude Therapeutics NASDAQ:PRLD

Rocket Pharmaceuticals NASDAQ:RCKT

X4 Pharmaceuticals NASDAQ:XFOR

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools